StockData

Cartesian Therapeutics, Inc. (RNAC) stock

RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$6.08−0.27 (-4.25%)

Close on Nov 16, 2026Market cap $183.95MP/E –Yield –

Cartesian Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Cartesian Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -10283.8%. For fiscal 2025 it was -4658.6%, against -199.0% the year before. The highest annual figure on record is 31.9% in fiscal 2022.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-4658.6%−4459.7
FY2024Dec 31, 2024-199.0%+645.9
FY2023Dec 31, 2023-844.9%−876.8
FY2022Dec 31, 202231.9%+62.1
FY2021Dec 31, 2021-30.2%+384.8
FY2020Dec 31, 2020-415.0%+414.0
FY2019Dec 31, 2019-829.0%+6406.5
FY2018Dec 31, 2018-7235.4%+24320.6
FY2017Dec 31, 2017-31556.0%−31108.1
FY2016Dec 31, 2016-448.0%−29.2
FY2015Dec 31, 2015-418.8%+4.9
FY2014Dec 31, 2014-423.7%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2026Mar 31, 2026-50233.3%−48623.3
Q4 FY2025Dec 31, 2025-9775.7%−3526.9
Q3 FY2025Sep 30, 2025-7942.9%−7984.3
Q2 FY2025Jun 30, 20255330.9%+6303.9
Q1 FY2025Mar 31, 2025-1610.0%+539.3
Q3 FY2024Sep 30, 2024-6248.8%−6111.4
Q2 FY2024Jun 30, 202441.4%+258.3
Q1 FY2024Mar 31, 2024-973.0%−608.2
Q4 FY2023Dec 31, 2023-2149.3%−2184.3
Q3 FY2023Sep 30, 2023-137.4%−99.3
Q2 FY2023Jun 30, 2023-216.9%−238.8
Q1 FY2023Mar 31, 2023-364.8%−449.5
Q4 FY2022Dec 31, 202235.1%−5.8
Q3 FY2022Sep 30, 2022-38.1%+35.1
Q2 FY2022Jun 30, 202221.9%−1.3
Q1 FY2022Mar 31, 202284.6%+307.2
Q4 FY2021Dec 31, 202140.9%+170.1
Q3 FY2021Sep 30, 2021-73.3%+136.2
Q2 FY2021Jun 30, 202123.2%+247.0
Q1 FY2021Mar 31, 2021-222.6%+125885.1
Q4 FY2020Dec 31, 2020-129.2%+120610.8
Q3 FY2020Sep 30, 2020-209.4%+1413.1
Q4 FY2019Dec 31, 2019-223.7%+114741.0
Q2 FY2019Jun 30, 2019-126107.7%−71752.1
Q1 FY2019Mar 31, 2019-120740.0%−59328.5
Q4 FY2018Dec 31, 2018-1622.5%+9424.2
Q4 FY2017Dec 31, 2017-114964.7%−114484.1
Q3 FY2017Sep 30, 2017-54355.6%−53618.2
Q2 FY2017Jun 30, 2017-61411.5%–
Q1 FY2017Mar 31, 2017-11046.7%–
Q4 FY2016Dec 31, 2016-480.6%–
Q3 FY2016Sep 30, 2016-737.4%–

More Cartesian Therapeutics figures

See a number that looks wrong?